Q&A With David Blum From Sunovion Pharmaceuticals: Learning More About Aptiom To Help Patients With Epilepsy

Treating epilepsy can be an effort in individualized medicine with different patients reacting differently to the various seizure medications available. Finding the right one can often determine a patient's quality of life moving forward after diagnosis.

David Blum, MD, MA, Executive Medical Director for Sunovion Pharmaceuticals discussed the role Aptiom can play in that process especially after receiving approval from the US Food and Drug Administration to provide the medication as a monotherapy in addition to being combined with other treatment options during the annual meeting of the American Epilepsy Society in Philadelphia.